BR0213776A - Método e composição farmacêutica para o tratamento ou a prevenção de bexiga superativa ou incontinência urinária em um indivìduo, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxoperhidropirimidin- 1-il) piperidino]butil]-n-metilbenzamida ou um sal farmaceuticamente aceitável da mesma - Google Patents

Método e composição farmacêutica para o tratamento ou a prevenção de bexiga superativa ou incontinência urinária em um indivìduo, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxoperhidropirimidin- 1-il) piperidino]butil]-n-metilbenzamida ou um sal farmaceuticamente aceitável da mesma

Info

Publication number
BR0213776A
BR0213776A BR0213776-3A BR0213776A BR0213776A BR 0213776 A BR0213776 A BR 0213776A BR 0213776 A BR0213776 A BR 0213776A BR 0213776 A BR0213776 A BR 0213776A
Authority
BR
Brazil
Prior art keywords
prevention
treatment
oxoperhydropyrimidin
methylbenzamide
individual
Prior art date
Application number
BR0213776-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Russell Bialecki
Cathy Dantzman
Keith Herzog
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0213776A publication Critical patent/BR0213776A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
BR0213776-3A 2001-11-02 2002-11-01 Método e composição farmacêutica para o tratamento ou a prevenção de bexiga superativa ou incontinência urinária em um indivìduo, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxoperhidropirimidin- 1-il) piperidino]butil]-n-metilbenzamida ou um sal farmaceuticamente aceitável da mesma BR0213776A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103668A SE0103668D0 (sv) 2001-11-02 2001-11-02 Method for the treatment of overactive blader
PCT/SE2002/001990 WO2003037341A1 (en) 2001-11-02 2002-11-01 Method for the treatment of overactive bladder

Publications (1)

Publication Number Publication Date
BR0213776A true BR0213776A (pt) 2004-11-09

Family

ID=20285870

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213776-3A BR0213776A (pt) 2001-11-02 2002-11-01 Método e composição farmacêutica para o tratamento ou a prevenção de bexiga superativa ou incontinência urinária em um indivìduo, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxoperhidropirimidin- 1-il) piperidino]butil]-n-metilbenzamida ou um sal farmaceuticamente aceitável da mesma

Country Status (13)

Country Link
US (1) US20040248914A1 (https=)
EP (1) EP1450805A1 (https=)
JP (1) JP2005511561A (https=)
KR (1) KR20050042211A (https=)
CN (1) CN1622806A (https=)
BR (1) BR0213776A (https=)
CA (1) CA2465140A1 (https=)
IL (1) IL161599A0 (https=)
MX (1) MXPA04004071A (https=)
NO (1) NO20042139L (https=)
SE (1) SE0103668D0 (https=)
WO (1) WO2003037341A1 (https=)
ZA (1) ZA200403199B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121389A1 (en) * 2005-05-10 2006-11-16 Astrazeneca Ab Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity
TWI667034B (zh) * 2016-09-21 2019-08-01 惠眾生技股份有限公司 關刀豆用於製備保護膀胱避免損傷藥劑之用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE300218B (https=) * 1960-11-08 1968-04-22 Recip Ab
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
GB9505084D0 (en) * 1995-03-14 1995-05-03 Pfizer Ltd Benzamide derivative
GB9922519D0 (en) * 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9924141D0 (en) * 1998-10-30 1999-12-15 Zeneca Ltd Treatment of gastric asthma
GB9826941D0 (en) * 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence

Also Published As

Publication number Publication date
US20040248914A1 (en) 2004-12-09
CN1622806A (zh) 2005-06-01
JP2005511561A (ja) 2005-04-28
SE0103668D0 (sv) 2001-11-02
EP1450805A1 (en) 2004-09-01
NO20042139L (no) 2004-06-25
KR20050042211A (ko) 2005-05-06
ZA200403199B (en) 2005-02-09
MXPA04004071A (es) 2004-09-06
WO2003037341A1 (en) 2003-05-08
IL161599A0 (en) 2004-09-27
CA2465140A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
BR0215158A (pt) Derivados de pirrolidina e piperidina como antagonistas de nk1
BRPI0314308B8 (pt) antagonistas de opióide, seus usos, e composição farmacêutica
NO941647L (no) Heteroarylpiperidiner, pyrrolidiner og piperaziner og deres anvendelse som antipsykotika og analgetika
FI973446A0 (fi) Bentsyylipiperidiinit ja piperatsiinit muskariiniantagonisteina
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
NO20065477L (no) Kombinasjoner omfattende antimuskarinmidler og PDE4-inhibitorer
ATE224884T1 (de) Muscarin-antagonisten
BR0016611A (pt) Moduladores de neurotransmissão de dopamina
RU93043528A (ru) Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
DE602004006166D1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
DK0777666T3 (da) Substituerede piperidiner anvendelige ved behandling af allergiske sygdomme
ECSP066313A (es) Derivados de la piridazina y su uso como agentes terapéuticos
ECSP066315A (es) Derivados de la piridazina y su uso como agentes terapéuticos
BRPI0015254C1 (pt) compostos derivados de carbamoiloxialquil-azólio, seu uso, bem como composição farmacêutica compreendendo os mesmos.
AR003966A1 (es) Un derivado de difenilmetilenpiperidina, composición farmacéutica que lo contiene, metodo de preparación de dicho derivado y uso de este ultimo para preparar un medicamento
BR0309028A (pt) Compostos policìclicos como antagonistas potentes de alfa2-adrenoceptores
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
BR0009225A (pt) Uso de um antagonista de nmda de baixa afinidade,e, método para tratar ou prevenir a depressão emum mamìfero
BR0314843A (pt) Novo composto
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
MX2023007287A (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas.
BRPI0409881A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR0213832A (pt) Composto, método para tratamento ou prevenção de bexiga superativa ou incontinência urinária em um indivìduo, composição farmacêutica, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxo-piperidin-1-il)piperi dino]butil]-n-metil-2-fluorobenzamida ou um sal farmaceuticamente aceitável da mesma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O E 7O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2034 DE 29/12/2009.